Cytosorbents (CTSO) Cash & Equivalents (2010 - 2026)

Cytosorbents (CTSO) has reported Cash & Equivalents for 17 consecutive years, with $4.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents fell 56.75% year-over-year to $4.4 million; the trailing twelve-month figure through Jun 2026 stood at $4.4 million (down 56.75% YoY), and the FY2025 full-year result was $6.2 million, down 36.0% from the prior year.
• Cash & Equivalents slipped to $4.4 million in Q2 2026 per CTSO's latest filing, from $4.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $43.0 million in Q1 2022 and bottomed at $4.4 million in Q2 2026.
• Historically, Cash & Equivalents has averaged $14.0 million across 5 years, with a median of $10.0 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Cash & Equivalents jumped 52.29% in 2025, then tumbled 63.29% in 2026.
• Over 5 years, Cash & Equivalents stood at $22.1 million in 2022, then plunged by 36.19% to $14.1 million in 2023, then tumbled by 30.9% to $9.8 million in 2024, then plunged by 36.0% to $6.2 million in 2025, then retreated by 29.38% to $4.4 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $4.4 million, $4.8 million, and $6.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.